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 Figure 1: a) Effective doses and b) LYL-ratios. 
 
Conclusions: The LYL attributable to cancer therapy were orders of 
magnitudes larger than the LYL attributable to the diagnostic scans 
used for radiotherapy planning. However, the uncertainty in the 
present estimates of LYL were considerable, and would benefit from 
more exact risk models.  
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Purpose/Objective: Patient-(age, performance status, psychological 
distress), disease-(type, localization) and treatment (neurosurgery, 
radiotherapy, chemotherapy)-related factors may impact on cognitive 
functioning of metastasis patients. Neuropsychological involvement 
may be an important factor, reducing quality of daily life (QoL). This 
study aimed to evaluate difference between whole brain radiotherapy 
(WBRT) and radiosurgery (SRS) on neurocognitive functioning 
accordingly on QoL of brain metastasis patients. We did a randomized 
controlled trial to test our prediction. 
Materials and Methods: Patients with solitary brain metastasis of solid 
tumors with stable systemic disease tumors and KPS >/= 70 were 
treated with complete surgery and randomly assigned to adjuvant 
WBRT (30 Gy in 10 fractions) or SRS (17-20 Gy single fraction) on 
surgical cavity (max diameter 3.5 cm). The primary end point was 
local control, secondary end points survival, quality of life and 
toxicity. 65 patients, fulfilling the study inclusion criteria, were 
treated since December 2009 to September 2012. After randomization 
42 subjects were assigned to SRS group, 23 to WBRT. All subjects were 
tested to assessed global cognitive functioning using the Mini Mental 
State Examination (MMSE): at baseline (T1) before radiotherapy 
treatment, after one year (T2) and after 2 years (T3). Preliminary 
results were available for 55 subjects at T1, for 25 subjects at T2, for 
6 at T3. 
Results: The pretreatment MMSE was available for 37 patients 
randomized for SRS, and 18 for WBRT. The sample did not present 
cognitive deficit post surgery and no statistically significant difference 
were found between the baseline MMSE of two groups (P = 0,064). Of 
the 25 patients underwent the follow–up MMSE at one year, 10 (40%) 
had improved their scores and 5 (20%) worsened in SRS group; all 
subjects (100%) obtained lower scores in WBRT group. From 
preliminary evaluations it was found a statistically significant 
difference between the neurocognitive performance of WBRT group 
and the SRS one (P = 0,039). Currently, there’s no sufficient data at 2 
years. 
Conclusions: The results of this study have revealed that the long – 
term adverse effect of WBRT on neurocognitive functioning might not 
be negligible also for the quality of life of brain metastases patients.  
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Purpose/Objective: Many studies have assessed the fractionation 
scheme to choose the most appropriate in individual cases. Various 
fractionation schemes can provide a response equivalent to the 
control of pain, although longer treatment has the advantage of a 
lower incidence of reprocessing the same site. The aim of our 
retrospective study was to evaluate the differences in requirements 
and the impact of different radiotherapy schedules on patients 
symptoms in relationship to primary tumor type and quality of life. 
Materials and Methods: We analyzed 458 treatments of palliative 
radiotherapy for bone metastases. For these patients, we did control 
of pain, performance status and pain-therapy, before treatment, after 
treatment, and 180 days after the end of treatment. We analyzed the 
data using the T-test for paired data and the ANOVA test and we 
performed a comparison of performance status and pain in relation to 
the type of fractionation. 
Results: We noticed an improvement in performance status and pain 
relief in all groups, but the pain improvement was more evident in 
patients treated with single fraction, while we noticed a difference of 
the average KI before and after RT, even if not statistically 
significant, in favor of the longest fractionation (30 Gy) schemes. We 
also have focused our attention in patients with primary tumors with 
expected greater overall survival, in particular, we considered 
patients treated for bone metastases from breast cancer. The 
differences between averages with ANOVA test seemed to 
demonstrate an advantage in favor of the 30Gy schedule for the KI (ns 
p = 0.105), while they were favorable to the single fraction of 8 Gy for 
the NRS (p <0.001). 
Conclusions: We have obtained data which are in line with the 
statement made in recent years on the equivalence of the various 
types of fractionation for the control of pain from bone metastases, 
but that suggest a greater attention to the radiation oncologist in the 
choice of the patient to be subjected to various types of 
fractionation. It is recommended to put a considerable amount of 
attention over which the clinical condition of patients, the primary 
tumor (breast) of patients who, for the greater life expectancy 
resulting from the natural history of cancer, should have a better 
access to a more prolonged treatment. 
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Purpose/Objective: This retrospective analysis reports the outcomes 
obtained with an original once weekly stereotactic radiotherapy 
fractionation delivered for patients affected by evolving 
oligometastases from different solid malignancies. 
Materials and Methods: From 2009 to 2011 patients with symptomatic 
and/or evolving oligometastases were submitted to a median 5-
fraction-cycle of stereotactic radiotherapy by delivering only one a 
fraction per week in order to exploit a radiobiological rationale 
designed to increase the therapeutic index. Individual fractionation 
was mainly planned according to patient performance status, 
oligometastases size and site and record of previous irradiation in the 
same site. 
Results: Thirty-six patients in stage IV UICC-TNM affected by 
oligometastases were treated with image-guided/intensity modulated 
stereotactic tomotherapy by delivering a single weekly radiation. 
Median age was 70 yrs (34-89 yrs). The median weekly single dose, 
number of fractions and overall total radiation dose were 7 Gy, 5 
fractions and 35 Gy, respectively. Thirty-five (97%) patients 
completed the treatment schedule. No patient suffered mild or severe 
radiation-related side effects. Twenty-one (87%) out of 24 patients 
with local pain had complete symptomatic response within 30 days 
from the end of radiotherapy. Local control assessed at imaging after 
SRT was evidenced in 30 (83%) of patients. Median time to response 
after the end of radiotherapy was 40 days . 
